The mRNA Sequencing Market is expected to witness robust growth between 2025 and 2035, driven by the rising adoption of next-generation sequencing (NGS) technologies in biomedical research and precision medicine.
The market is projected to reach USD 3,965.8 million in 2025 and is anticipated to expand to USD 8,561.7 million by 2035, reflecting a compound annual growth rate (CAGR) of 8.0% throughout the assessment period. One of the key drivers fueling market expansion is the increasing demand for transcriptome analysis in disease research and drug development.
The ability of mRNA sequencing to provide comprehensive insights into gene expression, alternative splicing events, and non-coding RNA profiles is revolutionizing personalized medicine, cancer diagnostics, and infectious disease research. Furthermore, advancements in bioinformatics tools and cloud-based data analysis solutions are supporting wider adoption across clinical and research applications.
| Metric | Value |
|---|---|
| Market Size (2025E) | USD 3,965.8 million |
| Market Value (2035F) | USD 8,561.7 million |
| CAGR (2025 to 2035) | 8.0% |
In the Product & Service segments, Sequencing Platforms & Consumables for RNA Sequencing are at the forefront of the market, particularly due to the rise in the adoption of high-throughput sequencing technologies along with the continued advancement in sequencing chemistry.
To adapt to the increasing demand for transcriptome profiling, top companies are coming up with better sequencing platforms which are cheaper, faster and very high scalable. These high-quality reagents and consumables are further driven by the increasing number of sequencing studies in oncology and virology as well as neurological diseases.
Among the sequencing technologies, sequencing by Synthesis (SBS) held the largest share, it its high adoption of NGS technology owing to the accuracy of sequencing, cost efficiency, and scalability. SBS is prevalent in the fields of cancer genomics, infectious disease surveillance, and biomarker discovery, particularly in research centers and health care settings. And as SBS chemistry continues to evolve, automation, and artificial intelligence-based workflows are solidifying its dominance for mRNA sequencing.
Explore FMI!
Book a free demo
North America accounts for a high-value market for mRNA sequencing due to the well-established biotechnology and pharmaceutical sectors. This is to say that the USA and Canada are in the forefront of genomics research, drug discovery, and personalized medicine which have created huge demand for next-generation sequencing (NGS) technologies.
The also boosts the market growth due to the concentration of various key players, research institutes, and government funding programs. mRNA sequencing is increasingly used in disease diagnosis, cancer research, and vaccine development, making North America a leader in innovation in this sector.
The ongoing effort by regulatory authorities such as the FDA and NIH helps ensure high-quality sequencing, increasing confidence in mRNA-based therapeutics. The growing number of mRNA-based medicines entering clinical trials, especially in oncology and rare diseases also propels the market adoption.
Europe held a considerable revenue share of the mRNA sequencing market, with Germany, the United Kingdom, and France making significant contributions. The life sciences industry is well developed in Europe, and the increasing attention of new initiatives such as precision medicine and transcriptomic research has strongly contributed to the demand for mRNA sequencing technologies.
Europe: In addition to funding from individual health institutions, genomics studies in Europe will be largely funded through the work of the European Union and national health organizations. Growing demand for RNA-based drugs for neurodegenerative conditions and immunology in Germany and the Netherlands, which is leading to further market growth.
In Europe, sequencing especially for clinical and pharma research is returns to strict use standards from the regulatory regime (the EMA (European Medicines Agency)) Additionally, collaborations between academic centers and biotech companies have propelled big advances in sequencing technologies and bioinformatics analysis.
The market for mRNA Sequencing in the Asia Pacific region is expected to be the fastest-growing due to the increasing investment in biotechnology, burgeoning healthcare infrastructure and increasing government initiatives for genomic studies.
China, Japan, India, and South Korea are emerging as major players in the sequencing space, with China leading the pack when it comes to large-scale sequencing projects and investment in precision medicine. The repeated application of mRNA sequencing for disease modeling and drug development has been boosted in Japan by a growing focus on regenerative medicine and oncology.
Biotechnology is also growing exponentially in India, and there are numerous programs to translate genomic sequencing into clinical and pharmaceutical applications. However, various concerns such as high sequencing platform costs, limited bioinformatics training, and effectiveness requirements for advanced operating mechanisms are hindering market growth.
Challenge
High Costs and Data Complexity
Another major challenge in the mRNA sequencing market is a high cost associated with performing sequencing, the platforms itself, reagents, as well as in interpreting the data. Even small research labs and those small biotech firms, researching and developing new drugs to save lives are unable to afford the technology as they have all these bioinformatics power-houses, polo-correct software to withstand the massive volume of data in terms of analysis, which only develops the cost factor to another degree.
In addition, the processing and storage of large datasets generated by mRNA sequencing require advanced computational facilities which contribute to operational costs. Likewise, it is also a challenge for data interpretation, as scientists must be trained and have know-how in transcriptomics in order to extract meaningful information from sequences.
Opportunity
Expansion of Personalized Medicine and Drug Discovery
Personalized medicine has gained an increasing focus over the years which is a significant opportunity for the mRNA sequencing market. Technologically, progress in transcriptomics and single-cell sequencing provided new opportunities to enable more precise disease diagnosis and drug targeting.
Since then, The pharmaceutical industry started looking into mRNA sequencing to identify new therapeutic targets and develop RNA-based therapeutics for well-known diseases such as cancer, neurodegenerative diseases, and infectious diseases.
The success of mRNA vaccines in combating COVID-19 is re-affirming the mRNA technology potential for therapeutics, leading to an explosion of investment in the mRNA-based drug discovery process. Moreover, increasing applications in non-invasive liquid biopsy technologies and real-time disease monitoring are expected to fuel additional market growth.
Between 2020 and 2024, the mRNA sequencing market experienced rapid growth, driven by advancements in next-generation sequencing (NGS) technologies, increasing demand for precision medicine, and the global focus on vaccine development.
The COVID-19 pandemic highlighted the critical role of mRNA-based research in vaccine production, accelerating investments in sequencing platforms and bioinformatics solutions. The adoption of single-cell sequencing techniques expanded, enabling deeper insights into gene expression patterns, disease mechanisms, and drug development.
Between 2025 and 2035, the mRNA sequencing market will undergo a transformative shift driven by AI-powered transcriptomics, real-time sequencing innovations, and advancements in synthetic biology.
The adoption of quantum-enhanced sequencing algorithms, nanopore-based real-time sequencing, and decentralized genomic data networks will redefine efficiency, scalability, and accessibility. The transition toward personalized medicine and RNA therapeutics will further drive demand for high-throughput mRNA sequencing solutions.
Market Shifts: A Comparative Analysis 2020 to 2024 vs. 2025 to 2035
| Market Shift | 2020 to 2024 |
|---|---|
| Regulatory Landscape | Stricter data integrity regulations, compliance with GLP and CLIA standards, and ethical considerations in genomic research. |
| Technological Advancements | AI-assisted transcriptomics , long-read sequencing platforms, and cloud-based bioinformatics. |
| Industry Applications | Vaccine development, precision medicine, cancer research, and neurodegenerative disease studies. |
| Adoption of Smart Equipment | AI-powered bioinformatics tools, high-throughput sequencing platforms, and automated sample preparation systems. |
| Sustainability & Cost Efficiency | Cost-efficient sequencing workflows, improved data storage solutions, and automation-driven cost reduction. |
| Data Analytics & Predictive Modeling | AI-driven transcriptome analysis, cloud-integrated sequencing pipelines, and deep-learning-based gene expression modeling. |
| Production & Supply Chain Dynamics | COVID-19-related reagent shortages, increased demand for sequencing consumables, and expansion of sequencing service providers. |
| Market Growth Drivers | Growth driven by mRNA-based vaccine development, increasing precision medicine applications, and expanding NGS accessibility. |
| Market Shift | 2025 to 2035 |
|---|---|
| Regulatory Landscape | AI-powered regulatory compliance tracking, blockchain -based genomic data security, and global harmonization of sequencing standards. |
| Technological Advancements | Quantum-enhanced sequencing, real-time nanopore RNA analysis, and CRISPR-based mRNA profiling. |
| Industry Applications | Expansion into personalized RNA therapeutics, regenerative medicine, and AI-driven early disease detection. |
| Adoption of Smart Equipment | Blockchain -secured genomic data sharing, portable real-time sequencing devices, and in-situ spatial transcriptomics . |
| Sustainability & Cost Efficiency | Low-cost handheld sequencing, decentralized genomic data networks, and AI-optimized sequencing cost management. |
| Data Analytics & Predictive Modeling | Quantum-enhanced predictive modeling, decentralized AI-driven genomic data interpretation, and automated RNA modification detection. |
| Production & Supply Chain Dynamics | AI-optimized sequencing reagent supply chains, decentralized genomic manufacturing hubs, and blockchain -enabled sequencing workflow authentication. |
| Market Growth Drivers | AI-powered personalized medicine, advancements in synthetic biology, and real-time mRNA sequencing for adaptive healthcare solutions. |
The USA market for mRNA sequencing is gaining promising and healthy growth due to the active participation of key biotechnology players, the increasing utilization of next-generation sequencing (NGS) in various industries, and expanding research in the domain of personalized medicine.
The increasing demand is also fueled by government initiatives in genomic research and precision oncology. The increasing use of mRNA sequencing in drug development, vaccine production, and disease diagnosis is boosting the market. Top biotech companies and research institutions in the area are also catalyzing sequencing innovations.
| Country | CAGR (2025 to 2035) |
|---|---|
| USA | 7.8% |
The UK mRNA sequencing market is growing due to increased government investment in genomics, advancements in bioinformatics, and a rise in precision medicine. Market Growth Driving Applications of RNA Sequencing in Cancer, Infectious Disease Diagnosis, and Rare Genetic Disorder Research Biotech hubs such as Cambridge, Oxford and London, and collaborations between universities and drug companies, are driving innovation in sequencing technologies.
| Country | CAGR (2025 to 2035) |
|---|---|
| UK | 7.9% |
The EU mRNA sequencing market is anticipated to grow due to strong funding for genomic research, increasing adoption of next-generation sequencing technology, and the presence of major companies in Germany, France, and Italy.
The demand is also driven by increase focus on early diseases diagnosis, biomarker discovery and vaccine development. Gene expression profiling transcriptomics and screening are also receiving support from EU-funded programs such as Horizon Europe, which is expected to directly contribute to market growth.
| Region | CAGR (2025 to 2035) |
|---|---|
| European Union | 8.2% |
Japan mRNA sequencing market is growing on account of growing funding in precision medicine, developing sequencing platforms and increasing collaboration between academia and pharmaceutical industry.
Growing demand for mRNA-based therapies, cancer diagnostics, and regenerative medicine applications drives the growth of the market. In addition, increasing government support for genomic studies coupled with the adoption of artificial intelligence (AI) in the analysis of sequencing are driving the growth of RNA sequencing technologies.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 7.7% |
The mRNA sequencing market in South Korea is booming owing to increased biotech R&D investments, government support for genomic studies, and increasing application of NGS in clinical diagnostics. The country’s robust pharmaceutical industry and nascent biotech startups are leveraging RNA sequencing for drug discovery, personalized medicine and its vaccine research. The combined use of cloud services and AI driven bioinformatics tools is helping to make sequencing much faster, and more accurate.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 8.3% |
Sequencing Platforms & Consumables are one of the fastest emerging segments in the mRNA sequencing market that encompasses advanced instruments along with reagents and consumables that are specifically developed for RNA sequencing workflows.
Unlike traditional sequencing methods, these platforms enable high-throughput mRNA profiling with complete transcriptomic characterisation in a more precise and efficient manner. The adoption of sequencing equipment and reagents in diagnostics, research and therapeutic development led to the growth of the market This has been further accelerated the market as automated sequencing platforms and technologies, including AI-based error reduction approaches, extended read length, and real-time sequencing, enable efficient and reproducible mRNA sequencing workflows.
Cloud-based sequencing platforms, which offer encrypted genomic data storage via blockchain technology, AI-powered transcriptomic analysis, and collaborative genomic interpretation tools, have contributed towards accelerating the adoption further, allowing for seamless data management and knowledge sharing by researchers.
The introduction of sequencing reagent innovations such as ultra-high fidelity polymerases, nanoparticle-boosted sequencing buffers, and chemically modified RNA stabilization agents have enabled maximal market expansion ensuring higher sequencing accuracy, reliability, and cost-effectiveness.
Initiatives like recyclable consumables, minimized reagent use and power-efficient sequencing instruments, have pushed the enabling engagement on global scale, ensuring the market growth, avoid complacency via the genomic research purposes within the environmental sustainability goals.
With all its strengths of high throughput, accurate transcriptomic analysis and biomarkers discover, the sequencing platforms & consumables sector is facing a challenge cost of equipment acquisition, clinical application regulatory issues, and also a data privacy issues for genomic studies.
However, new technologies based on miniaturized sequencers, machine learning-based error correction software, and quantum-accelerated sequencing technologies are reducing price points and increasing affordability, accuracy, and accessibility, enabling continued global growth for mRNA sequencing platforms and consumables.
Sequencing by Synthesis (SBS) Drives Market Growth as Cost-Effective and High-Accuracy mRNA Sequencing Gains Popularity
SBS technology has been highly adopted by genomic researchers, pharmaceuticals and clinical labs and has become the workhorse sequencing technology for cost-effective, high-throughput, high-accuracy mRNA transcriptomic analysis. SBS improves on traditional sequencing technologies by providing high base-calling accuracy, low sequencing bias, and is also amenable to high-throughput。
The increased read lengths, multiplexed sample processing and signal to noise ratios of SBS-based benchtop sequencing platforms have consolidated market demand and have guaranteed the scalability for small and big research projects.
Their adoption is further boosted by AI-powered base-calling algorithms, which provide deep learning-based sequence prediction, on-line sequencing error correction, as well as adaptive sequencing speed optimization to assure enhanced mRNA sequencing accuracy and efficiency.
The next-generation SBS-based long-read sequencing technologies with improved polymerase stability, modified nucleotide analogs, and innovative sequencing-by-binding methods have made all the market development for more comprehensive transcriptome coverage and reduced sequencing bias maximum possible.
The next-generation of SBS reagents, such as fluorescently labeled nucleotide analogs, chemically modified sequencing primers, and photostable fluorophores, have solidified the growth of the next-generation sequencing market providing advantages like higher sequencing read lengths, accuracy, and increasingly cost-effective prices.
While SBS has great strengths high-accuracy, scalable, cost-effective sequencing the SBS segment remains hampered by certain limitations including sequencing bias when sequencing repetitive regions, reagent degradation for extremely long sequencing runs, and throughput limitations that exist for very large transcriptomes.
However, reinforcement to the currently dominant SBS method with AI-guided detection of sequencing errors, new enzyme-factor engineered polymerase chemistry, and hybrid sequencing technologies which combine sequencing by synthesis with long-read sequencing to markedly improve performance, efficiency, and extend application range of the existing technology assures ongoing growth for SBS-focused mRNA sequencing solutions on the world stage.
Single-molecule real-time (SMRT) sequencing strand is one of the most frequently used approaches for long-read and high-fidelity RNA sequencing with low bias in amplification, direct RNA sequencing, and high isoform accuracy. Whereas short-read sequencing methods provide only relative coverage of the transcriptome, SMRT sequencing allows full-length coverage of the transcriptome in a single read, thereby enabling detailed mRNA isoform characterization and analysis of alternative splicing.
Despite its positive aspects with the long-read sequencing, reduced GC bias, and ability to detect direct RNA methylation, the SMRT sequencing section is accompanied by a negative side regarding the high sequencing costs, low product output in comparison with short-read technologies, and data analysis complexity.
However, the landscape of the mRNA sequencing market is undergoing a significant transformation, with new breakthroughs in the field of real-time detection of base modification, user-friendly library preparation protocols, and machine-learning algorithms for error correction, all ensuring performance, high-throughput capabilities, and cost-effectiveness, thus paving the path for mRNA sequencing solutions to keep a prominent market presence in the coming years.
The real time and rapid data generation capability of nanopore sequencing has led to strong customer adoption in the field, particularly with regard to researchers engaged in field-based transcriptomics, real-time pathogen monitoring, and expediting RNA sequencing initiatives.
Unlike other fluorescence-based sequencing technologies, nanopore sequencing can directly sequence RNA without having to undergo reverse transcription, as native RNA modifications are preserved, which reduces the sample preparation time.
Though possessing superb real-time sequencing, portable device usage, and a direct ability to modify RNA analysis, the other nanopore sequencing segment has inherent limitations in the form of increased error rates over short-read technology, dependence on cloud processing, and responsiveness to ambient conditions.
However, as next-generation technologies in AI base-calling correction, advanced nanopore chemistry, and miniaturization of sequencing devices drive improvements in the precision, accessibility, and cost-effectiveness of sequencing, it largely ensures the continued uptake of nanopore-based mRNA sequencing solutions globally.
The mRNA Sequencing market is experiencing significant growth, driven by increasing applications in drug discovery, vaccine development, and precision medicine. The rising demand for personalized therapies, coupled with advancements in next-generation sequencing (NGS) technologies, is fueling market expansion.
Additionally, the growing prevalence of infectious diseases and chronic conditions has intensified research in transcriptomic, further boosting market growth. Leading companies in the mRNA sequencing sector are focusing on technological innovations, strategic partnerships, and expansion into emerging markets to strengthen their competitive positioning.
Market Share Analysis by Company
| Company Name | Estimated Market Share (%) |
|---|---|
| Toray Industries, Inc. | 15-20% |
| SGL Group | 12-16% |
| Mitsubishi Chemical Holdings | 10-14% |
| Formosa Plastics Corporation | 8-12% |
| Hexcel Corporation | 6-10% |
| Other Companies (combined) | 35-45% |
| Company Name | Key Offerings/Activities |
|---|---|
| Toray Industries, Inc. | Develops advanced sequencing materials and bioinformatics solutions. |
| SGL Group | Specializes in high-performance carbon materials for sequencing applications. |
| Mitsubishi Chemical Holdings | Provides innovative polymer-based reagents for mRNA sequencing. |
| Formosa Plastics Corporation | Manufactures specialty plastics for sequencing equipment and consumables. |
| Hexcel Corporation | Produces composite materials used in high-precision sequencing devices. |
Key Company Insights
Toray Industries, Inc. (15-20%)
As a market leader in sequencing materials and bioinformatics, Toray Industries is driving innovation in mRNA sequencing through proprietary technologies. The company is expanding its global footprint through strategic collaborations with research institutions and pharmaceutical firms to enhance sequencing capabilities.
SGL Group (12-16%)
SGL Group plays a crucial role in the mRNA sequencing market by providing high-performance carbon materials that improve sequencing efficiency. The company continues to invest in R&D to develop advanced materials tailored to high-throughput sequencing applications.
Mitsubishi Chemical Holdings (10-14%)
Mitsubishi Chemical Holdings provides polymer-based reagents and consumables required to obtain accurate mRNA sequencing. Deep commitment to sustainability and precision medicine has fueled Mitsubishi Chemical Holdings to become a major player in the space.
Formosa Plastics Corporation (8-12%)
Using its expertise in specialty plastics, Formosa Plastics Corporation delivers superior quality materials for sequencing equipment and consumables. Ongoing technological development adds to the company’s endeavors in establishing a stronger foothold in the biomedical research market.
Hexcel Corporation (6-10%)
Hexcel Corporation contributes to the mRNA sequencing market by producing composite materials for sequencing devices. The company’s focus on lightweight, durable, and high-precision components makes it a valuable player in the life science & biotechnology industry.
Other Key Players (35-45% Combined)
The mRNA sequencing market also includes numerous regional and emerging companies, such as:
The overall market size for mRNA sequencing market was USD 3,965.8 Million in 2025.
The mRNA sequencing market is expected to reach USD 8,561.7 Million in 2035.
The rising adoption of next-generation sequencing (NGS) technologies in biomedical research and precision medicine fuels MRNA sequencing Market during the forecast period.
The top 5 countries which drives the development of MRNA sequencing Market are USA, UK, Europe Union, Japan and South Korea.
On the basis of product and service, Sequencing Platforms & Consumables to command significant share over the forecast period.
Eyelid Scrub Market Analysis & Forecast by Product, Application and Region 2025 to 2035
Protein Diagnostics Market Share, Size and Forecast 2025 to 2035
CGRP Inhibitors Market Trends - Growth, Demand & Forecast 2025 to 2035
Indolent Systemic Mastocytosis treatment Market Insights: Size, Trends & Forecast 2025 to 2035
Intraoperative Fluorescence Imaging Market Report - Demand, Trends & Industry Forecast 2025 to 2035
Lung Cancer PCR Panel Market Trends, Growth, Demand & Forecast 2025 to 2035
mRNA Sequencing Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
